Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success

Awaiting Word From AbbVie On Option Exercise

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

Woman applying eye drops on light background, closeup
Reproxalap's rapid efficacy may be differentiating in dry eye disease • Source: Shutterstock

Aldeyra Therapeutics, Inc. plans to resubmit reproxalap for US Food and Drug Administration approval to treat dry eye disease based on the positive outcome of a Phase III dye eye chamber clinical trial that the agency required before it would reconsider the company’s new drug application (NDA). Aldeyra plans to refile the NDA before the end of 2024 and expects a six-month review as it promised investors back in March when the FDA cleared the design of its chamber trial design.

Key Takeaways

  • Aldeyra reported Phase III data from a dry eye chamber study that will support resubmission of reproxalap to the US FDA.

The agency issued a complete response letter (CRL) in November 2023, denying approval of reproxalap, a reactive aldehyde species (RASP)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D